Search

Your search keyword '"Cashen, Amanda"' showing total 15 results
Start Over Author "Cashen, Amanda" Journal transplantation and cellular therapy
15 results on '"Cashen, Amanda"'

1. Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell Recipients with Large B Cell Lymphoma.

Author

Geethakumari, Praveen Ramakrishnan, primary, Wudhikarn, Kitsada, additional, Jain, Michael D., additional, Vallurupalli, Anusha, additional, Kim, Soyoung, additional, Oloyede, Temitope, additional, Awan, Farrukh T, additional, Mirza, Abu-Sayeef, additional, Bachanova, Veronika, additional, Badar, Talha, additional, Barba, Pere, additional, Beitinjaneh, Prof. Amer, additional, Cashen, Amanda, additional, Dholaria, Dr. Bhagirathbhai, additional, Elsawy, Mahmoud, additional, Farooq, Umar, additional, Foglesong, Jessica, additional, Ganguly, Siddhartha MD, additional, Greenbaum, Uri, additional, Hashmi, Hamza, additional, Hill, LaQuisa Chimere, additional, Jain, Dr. Tania, additional, Kebriaei, Partow, additional, Kittai, Adam S., additional, Locke, Frederick L., additional, Lulla, Premal D., additional, Mead, Elena, additional, McGuirk, Joseph P, additional, Mussetti, Alberto, additional, Nishihori, Taiga, additional, Olson, Amanda L., additional, Pennisi, Martina, additional, Perales, Miguel-Angel, additional, Riedell, Peter A., additional, Saber, Wael, additional, Shouval, Roni, additional, Shpall, Elizabeth J., additional, Sorror, Mohamed L., additional, Strouse, Christopher Sun, additional, Turtle, Cameron J., additional, Pasquini, Marcelo C., additional, Moskop, Amy, additional, and Ahmed, Sairah, additional

Published
2024
Full Text
View/download PDF

2. Donor-Derived Memory-like NK Cells for the Treatment of Children and Young Adults with Relapsed AML Following Allo-HCT

Author

Pfeiffer, Thomas, primary, Zimmerman, Clare, additional, Berrien-Elliott, Melissa M, additional, Foltz, Jennifer, additional, Becker-Hapak, Michelle, additional, Neal, Carly, additional, Foster, Mark, additional, Schappe, Timothy, additional, McClain, Ethan, additional, Pence, Patrick, additional, Desai, Sweta, additional, Wong, Pamela, additional, Russler-Germain, David, additional, Fisk, Bryan, additional, Wen-Rong, Lie, additional, Eisele, Jeremy, additional, Hyde, Stephanie, additional, Bhatt, Sima, additional, Griffith, Obi, additional, Griffith, Malachi, additional, Rueve, Joseph, additional, Pureti, Sushanth, additional, Cashen, Amanda, additional, Bednarski, Jeffrey J, additional, and Fehniger, Todd A, additional

Published
2024
Full Text
View/download PDF

3. Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma

Author

Slade, Michael, primary, Rettig, Michael P., additional, Crees, Zachary D, additional, Mehta-Shah, Neha, additional, Bartlett, Nancy L., additional, Fehniger, Todd A, additional, Cashen, Amanda, additional, Pusic, Dr. Iskra, additional, Uy, Geoffrey L., additional, Westervelt, Peter, additional, DiPersio, John F., additional, and Ghobadi, Armin, additional

Published
2024
Full Text
View/download PDF

4. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

8. A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Author

Abboud, Ramzi, primary, Gao, Feng, additional, Rettig, Michael P., additional, Abboud, Jeremy, additional, Gehrs, Leah, additional, Wallace, Nicholas, additional, Abboud, Camille, additional, Westervelt, Peter, additional, Uy, Geoffrey L., additional, Cashen, Amanda, additional, Christopher, Matthew, additional, Ghobadi, Armin, additional, Jacoby, Meagan, additional, Pusic, Iskra, additional, Stockerl-Goldstein, Keith, additional, DiPersio, John F., additional, and Schroeder, Mark A., additional

Published
2022
Full Text
View/download PDF

12. 386 - A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Author

Abboud, Ramzi, Gao, Feng, Rettig, Michael P., Abboud, Jeremy, Gehrs, Leah, Wallace, Nicholas, Abboud, Camille, Westervelt, Peter, Uy, Geoffrey L., Cashen, Amanda, Christopher, Matthew, Ghobadi, Armin, Jacoby, Meagan, Pusic, Iskra, Stockerl-Goldstein, Keith, DiPersio, John F., and Schroeder, Mark A.

Published
2022
Full Text
View/download PDF

14. A Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplant

Author

Xu, Ziheng, Choi, Jaebok, Cooper, Matthew, King, Jeffrey, Fiala, Mark A., Liu, Jingxia, Pusic, Iskra, Romee, Rizwan, Cashen, Amanda, Jacoby, Meagan A., Stockerl-Goldstein, Keith, Abboud, Camille, Vij, Ravi, Uy, Geoffrey, Westervelt, Peter, Walter, Matthew J., DiPersio, John F., and Schroeder, Mark A.

Abstract

•Early post-allo-HCT IV AZA starting on day +7 at 45mg/m2is overall well-tolerated•Post-transplant AZA has limited efficacy in preventing acute and chronic GvHD•This AZA schedule could have a beneficial effect in preventing disease relapse

Published
2023
Full Text
View/download PDF

15. Letermovir discontinuation at D+100 after Allogeneic Stem Cell Transplant is associated with increased CMV-related mortality

Author

Liu, Lawrence Wayne, Yn, Alicia, Gao, Feng, Olson, Marissa, Crain, Mallory, Abboud, Ramzi, Westervelt, Peter, Abboud, Camille, Vij, Ravi, Stockerl-Goldstein, Keith, Pusic, Iskra, Cashen, Amanda F., and Schroeder, Mark A.

Abstract

•Letermovir discontinuation at D+100 is associated with late reactivation of cytomegalovirus (CMV) and increased CMV-related mortality.•Total mortality benefit with letermovir was noted at 3-months but disappeared after 6 months.•Serum IgG levels < 400 mg/dL at D+100 was associated with increased late CMV reactivation.•Patients with subclinical CMV viremia before transplant, high risk transplants, post-transplant cyclophosphamide (PTCy) for acute graft versus host disease (aGVHD) prophylaxis, and mismatched-unrelated donors had decreased CMV reactivation with letermovir.•There was no difference in CMV reactivation in the CMV donor seropositive / recipient seronegative (CMV D+/R-) cohort overall.•The CMV D+/R- subset treated with PTCy for aGVHD prophylaxis had decreased CMV reactivation with letermovir.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results